Compounds > wy 45911
Page last updated: 2024-11-07

wy 45911

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Wy 45911: a leukotriene antagonist with lipoxygenase inhibiting activity; structure given in UD [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID129110
CHEMBL ID287012
SCHEMBL ID8181188
MeSH IDM0152435

Synonyms (13)

Synonym
wy 45911
CHEMBL287012 ,
wy-45911
n-hydroxy-n-[3-(quinolin-2-ylmethoxy)-phenyl]-succinamic acid methyl ester (wy-45,911)
n-hydroxy-n-[3-(quinolin-2-ylmethoxy)-phenyl]-succinamic acid methyl ester
bdbm50006801
methyl 4-[n-hydroxy-3-(quinolin-2-ylmethoxy)anilino]-4-oxobutanoate
4-(hydroxy-(3-(2-quinolinylnethoxy)phenyl)amino)-4-oxobutanoic acid methyl ester
wy-45,911
butanoic acid, 4-(hydroxy(3-(2-quinolinylmethoxy)phenyl)amino)-4-oxo-, methyl ester
105785-61-3
SCHEMBL8181188
DTXSID60147344
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyunsaturated fatty acid 5-lipoxygenaseRattus norvegicus (Norway rat)IC50 (µMol)1.40000.00462.018210.0000AID104166; AID3639; AID6799; AID6818
Prostaglandin G/H synthase 2 Rattus norvegicus (Norway rat)IC50 (µMol)40.13330.00291.786810.0000AID160873; AID160876; AID220183
Prostaglandin G/H synthase 1 Rattus norvegicus (Norway rat)IC50 (µMol)40.13330.00291.823210.0000AID160873; AID160876; AID220183
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyunsaturated fatty acid 5-lipoxygenaseRattus norvegicus (Norway rat)Inhibition1.53000.03500.78251.5300AID3642
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (37)

Assay IDTitleYearJournalArticle
AID192571Tested for metabolic activation counted as mean number of revertants in strains TA98, TA100, TA1535, and TA1538, three plates per treatment at 0.15 mg per plate, with activation provided by S-9 rat liver homogenates in Ames test1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Leukotriene D4 antagonists and 5-lipoxygenase inhibitors. Synthesis of benzoheterocyclic [(methoxyphenyl)amino]oxoalkanoic acid esters.
AID192560Tested for metabolic activation counted as mean number of revertants in strains TA98, TA100, TA1535, and TA1538, three plates per treatment at 0.005 mg per plate, without activation in the absence of S-9 rat liver homogenates in Ames test1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Leukotriene D4 antagonists and 5-lipoxygenase inhibitors. Synthesis of benzoheterocyclic [(methoxyphenyl)amino]oxoalkanoic acid esters.
AID166555The compound was tested for inhibition of translocation in SAR in RBL-2H3 cells1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID78034Compound was evaluated in vivo for the percent inhibition of Ovalbumin-induced (OA) bronchospasm in guinea pig at dose of 50 mg/kg id1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis of [[(naphthalenylmethoxy)- and [[(quinolinylmethoxy)phenyl]amino]oxoalkanoic acid esters. A novel series of leukotriene D4 antagonists and 5-lipoxygenase inhibitors.
AID73693Compound was evaluated for its effect on LTD4-induced contraction of guinea pig trachea1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis of [[(naphthalenylmethoxy)- and [[(quinolinylmethoxy)phenyl]amino]oxoalkanoic acid esters. A novel series of leukotriene D4 antagonists and 5-lipoxygenase inhibitors.
AID76183Ability to inhibit the Ovalbumin induced bronchospasm in guinea pig was determined in vivo at a dose of 50 mg/kg id1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Leukotriene D4 antagonists and 5-lipoxygenase inhibitors. Synthesis of benzoheterocyclic [(methoxyphenyl)amino]oxoalkanoic acid esters.
AID104166Ability to inhibit Lipoxygenase in vitro was determined1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Leukotriene D4 antagonists and 5-lipoxygenase inhibitors. Synthesis of benzoheterocyclic [(methoxyphenyl)amino]oxoalkanoic acid esters.
AID77094In vitro LTD4-induced bronchoconstriction. i n isolated guinea pig trachea by injecting intraduodenally.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
N-[(arylmethoxy)phenyl] carboxylic acids, hydroxamic acids, tetrazoles, and sulfonyl carboxamides. Potent orally active leukotriene D4 antagonists of novel structure.
AID192566Tested for metabolic activation counted as mean number of revertants in strains TA98, TA100, TA1535, and TA1538, three plates per treatment at 0.05 mg per plate, with activation provided by S-9 rat liver homogenates in Ames test1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Leukotriene D4 antagonists and 5-lipoxygenase inhibitors. Synthesis of benzoheterocyclic [(methoxyphenyl)amino]oxoalkanoic acid esters.
AID79843Compound was evaluated for its effect on LTC4-induced contraction of guinea pig trachea1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis of [[(naphthalenylmethoxy)- and [[(quinolinylmethoxy)phenyl]amino]oxoalkanoic acid esters. A novel series of leukotriene D4 antagonists and 5-lipoxygenase inhibitors.
AID224275The compound was tested for inhibition of thromboxane B2 synthesis1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID192567Tested for metabolic activation counted as mean number of revertants in strains TA98, TA100, TA1535, and TA1538, three plates per treatment at 0.05 mg per plate, without activation in the absence of S-9 rat liver homogenates in Ames test1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Leukotriene D4 antagonists and 5-lipoxygenase inhibitors. Synthesis of benzoheterocyclic [(methoxyphenyl)amino]oxoalkanoic acid esters.
AID192562Tested for metabolic activation counted as mean number of revertants in strains TA98, TA100, TA1535, and TA1538, three plates per treatment at 0.015 mg per plate, without activation in the absence of S-9 rat liver homogenates in Ames test1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Leukotriene D4 antagonists and 5-lipoxygenase inhibitors. Synthesis of benzoheterocyclic [(methoxyphenyl)amino]oxoalkanoic acid esters.
AID76181Inhibition of LTB4 induced bronchospasm in guinea pig was determined in at 50 mg/kg i.d.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Leukotriene D4 antagonists and 5-lipoxygenase inhibitors. Synthesis of benzoheterocyclic [(methoxyphenyl)amino]oxoalkanoic acid esters.
AID3642The compound was tested for inhibition of isolated 5-Lipoxygenase1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID151318In vitro inhibition of ovalbumin-induced bronchoconstriction in isolated guinea pig trachea was determined after intraduodenal aministration1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
N-[(arylmethoxy)phenyl] carboxylic acids, hydroxamic acids, tetrazoles, and sulfonyl carboxamides. Potent orally active leukotriene D4 antagonists of novel structure.
AID73692Compound was evaluated for its effect on LTC4-induced contraction of guinea pig trachea1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis of [[(naphthalenylmethoxy)- and [[(quinolinylmethoxy)phenyl]amino]oxoalkanoic acid esters. A novel series of leukotriene D4 antagonists and 5-lipoxygenase inhibitors.
AID23089-log dissociation constant was determined In vitro in isolated guinea pig trachea after intraduodenal administration (before 10 min)1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
N-[(arylmethoxy)phenyl] carboxylic acids, hydroxamic acids, tetrazoles, and sulfonyl carboxamides. Potent orally active leukotriene D4 antagonists of novel structure.
AID220183Ability to inhibit the rat PMN (polymorphonuclear leukocyte) CO (cyclo-oxygenase) in vitro was determined1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Leukotriene D4 antagonists and 5-lipoxygenase inhibitors. Synthesis of benzoheterocyclic [(methoxyphenyl)amino]oxoalkanoic acid esters.
AID78031In vivo inhibition of LTD4-induced bronchospasm in guinea pig at dose of 50 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis of [[(naphthalenylmethoxy)- and [[(quinolinylmethoxy)phenyl]amino]oxoalkanoic acid esters. A novel series of leukotriene D4 antagonists and 5-lipoxygenase inhibitors.
AID78083Compound was evaluated for its effect on LTD4-induced contraction of guinea pig trachea; percentage of maximal response of tissue to carbachol1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis of [[(naphthalenylmethoxy)- and [[(quinolinylmethoxy)phenyl]amino]oxoalkanoic acid esters. A novel series of leukotriene D4 antagonists and 5-lipoxygenase inhibitors.
AID224276The compound was tested for inhibitory activity against LTC4 synthesis in mouse peritoneal macrophages1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID192577Tested for metabolic activation counted as mean number of revertants in strains TA98, TA100, TA1535, and TA1538, three plates per treatment at 0.5 mg per plate, with activation provided by S-9 rat liver homogenates in Ames test1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Leukotriene D4 antagonists and 5-lipoxygenase inhibitors. Synthesis of benzoheterocyclic [(methoxyphenyl)amino]oxoalkanoic acid esters.
AID224274The compound was tested for inhibition of prostaglandin E2[PGE2] synthesis1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID79844Compound was evaluated for its effect on LTD4-induced contraction of guinea pig trachea1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis of [[(naphthalenylmethoxy)- and [[(quinolinylmethoxy)phenyl]amino]oxoalkanoic acid esters. A novel series of leukotriene D4 antagonists and 5-lipoxygenase inhibitors.
AID160873In vitro inhibition of rat polymorphonuclear leukocyte (PMN) Prostaglandin G/H synthase1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis of [[(naphthalenylmethoxy)- and [[(quinolinylmethoxy)phenyl]amino]oxoalkanoic acid esters. A novel series of leukotriene D4 antagonists and 5-lipoxygenase inhibitors.
AID3639The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS]1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID192695Tested for metabolic activation counted as mean number of revertants in strains TA98, TA100, TA1535, and TA1538, three plates per treatment at 0.5 mg per plate, without activation in the absence of S-9 rat liver homogenates in Ames test1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Leukotriene D4 antagonists and 5-lipoxygenase inhibitors. Synthesis of benzoheterocyclic [(methoxyphenyl)amino]oxoalkanoic acid esters.
AID192572Tested for metabolic activation counted as mean number of revertants in strains TA98, TA100, TA1535, and TA1538, three plates per treatment at 0.15 mg per plate, without activation in the absence of S-9 rat liver homogenates in Ames test1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Leukotriene D4 antagonists and 5-lipoxygenase inhibitors. Synthesis of benzoheterocyclic [(methoxyphenyl)amino]oxoalkanoic acid esters.
AID192561Tested for metabolic activation counted as mean number of revertants in strains TA98, TA100, TA1535, and TA1538, three plates per treatment at 0.015 mg per plate, with activation provided by S-9 rat liver homogenates in Ames test1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Leukotriene D4 antagonists and 5-lipoxygenase inhibitors. Synthesis of benzoheterocyclic [(methoxyphenyl)amino]oxoalkanoic acid esters.
AID224396The compound was tested for maximal inhibition against LTC4 synthesis in mouse peritoneal macrophages1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID78081Compound was evaluated for its effect on LTC4-induced contraction of guinea pig trachea; percentage of maximal response of tissue to carbachol1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis of [[(naphthalenylmethoxy)- and [[(quinolinylmethoxy)phenyl]amino]oxoalkanoic acid esters. A novel series of leukotriene D4 antagonists and 5-lipoxygenase inhibitors.
AID6799Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis of [[(naphthalenylmethoxy)- and [[(quinolinylmethoxy)phenyl]amino]oxoalkanoic acid esters. A novel series of leukotriene D4 antagonists and 5-lipoxygenase inhibitors.
AID6818Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
N-[(arylmethoxy)phenyl] carboxylic acids, hydroxamic acids, tetrazoles, and sulfonyl carboxamides. Potent orally active leukotriene D4 antagonists of novel structure.
AID166554The compound was tested for inhibition LTC4 synthesis1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID160876Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN (Prostaglandin G/H synthase).1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
N-[(arylmethoxy)phenyl] carboxylic acids, hydroxamic acids, tetrazoles, and sulfonyl carboxamides. Potent orally active leukotriene D4 antagonists of novel structure.
AID192559Tested for metabolic activation counted as mean number of revertants in strains TA98, TA100, TA1535, and TA1538, three plates per treatment at 0.005 mg per plate, with activation provided by S-9 rat liver homogenates in Ames test1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Leukotriene D4 antagonists and 5-lipoxygenase inhibitors. Synthesis of benzoheterocyclic [(methoxyphenyl)amino]oxoalkanoic acid esters.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (71.43)18.7374
1990's2 (28.57)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.26 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
aa 861
2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone: structure given in first source. docebenone : A member of the class of benzoquinones that is p-benzoquinone in which the hydrogens are substituted by three methyl groups and a 12-hydroxydodeca-5,10-diyn-1-yl group.		3.08101,4-benzoquinones;
acetylenic compound;
primary alcohol		EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor
ibuprofen
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine		1.9710monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
ly 171883
LY 171883: structure in first source; leukotriene receptor antagonist. tomelukast : A member of the class of acetophenones that is 1-phenylethanone substituted at position 2 by a hydroxy group, a propyl group at position 3 and a 4-(1H-tetrazol-5-yl)butoxy group at position 4. A leukotriene antagonist, it exhibits anti-asthmatic activity.		4.3260acetophenones;
aromatic ether;
phenols;
tetrazoles		anti-asthmatic drug;
leukotriene antagonist
masoprocol
nordihydroguaretic acid: antioxidant compound found in the creosote bush (Larrea tridentata)		3.0810catechols;
lignan;
tetrol		antioxidant;
ferroptosis inhibitor;
geroprotector;
plant metabolite
pf 5901
alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol: structure given in first source; platelet activating factor antagonist		3.7630quinolines
indazoles
Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.		1.9710indazole
bw-755c
4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine: A dual inhibitor of both cyclooxygenase and lipoxygenase pathways. It exerts an anti-inflammatory effect by inhibiting the formation of prostaglandins and leukotrienes. The drug also enhances pulmonary hypoxic vasoconstriction and has a protective effect after myocardial ischemia.		3.0810
lonapalene
RS 43179: used in treatment of psoriasis		3.0810naphthalenes;
organochlorine compound
tepoxalin
tepoxalin : A hydroxamic acid obtained by formal condensation of the carboxy group of 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propanoic acid with the amino group of N-methylhydroxylamine. It is used in veterinary medicine for the control of pain and inflammation caused by musculoskeletal disorders such as hip dysplasia and arthritis in dogs.		3.0810aromatic ether;
hydroxamic acid;
monochlorobenzenes;
pyrazoles		antipyretic;
apoptosis inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
immunomodulator;
lipoxygenase inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
zileuton
[no description available]		3.08101-benzothiophenes;
ureas		anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug
wy 48252
Wy 48252: leukotriene D4 antagonist		3.7630
cv 6504
CV 6504: structure given in first source		3.0810
fpl 55712
FPL 55712: inhibitor of SRS-A and LTC4 and LTD4 receptors		3.4820aromatic ketone
ici 198615
ICI 198615: an LTD4 receptor antagonist; SRS-A antagonist; structure given in first source		1.9710
sr 2640
SR 2640: leukotriene D4 and E4 antagonist		3.0810quinolines
rg 12525
RG 12525: leukotriene D4 antagonist; structure in first source		3.0810
eth 615
ETH 615: leukotriene B4 and interleukin-8 antagonist; structure in first source		3.0810
naproxen
Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.		3.0810methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
2-(phenylmethyl)-1-naphthol
2-(phenylmethyl)-1-naphthol: structure in UD		3.0810
arachidonic acid
icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.		1.9710icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid		Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite
l 663536
MK-886: orally active leukotriene biosynthesis inhibitor. 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid : A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of arachidonate 5-lipoxygenase.		3.0810aryl sulfide;
indoles;
monocarboxylic acid;
monochlorobenzenes		antineoplastic agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
leukotriene antagonist
thromboxane b2
Thromboxane B2: A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin).. thromboxane B2 : A member of the class of thromboxanes B that is (5Z,13E)-thromboxa-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15.		1.9710thromboxanes Bhuman metabolite;
mouse metabolite
bwa 4c
[no description available]		3.0810
tmk 688
TMK 688: structure given in first source		3.0810
chiniofon
Hydroxyquinolines: The 8-hydroxy derivatives inhibit various enzymes and their halogenated derivatives, though neurotoxic, are used as topical anti-infective agents, among other uses.		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials
Asthma, Bronchial
[description not available]		03.2920
Innate Inflammatory Response
[description not available]		02.8910
Disease, Pulmonary
[description not available]		02.8910
Asthma
A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).		03.2920
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.8910
Lung Diseases
Pathological processes involving any part of the LUNG.		02.8910
Bronchospasm
[description not available]		01.9710
Anasarca
[description not available]		01.9710
Bronchial Spasm
Spasmodic contraction of the smooth muscle of the bronchi.		01.9710
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		01.9710
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		02.8840